9.90
+0.03
(0.30%)
Jun 18 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 9.78 - 10.40 |
| 52 week | 4.02 - 10.40 |
| Open | 9.96 |
| Vol / Avg. | 71,539.00/99,271.00 |
| Mkt cap | 356.47M |
| P/E | - |
| Div/yield | - |
| EPS | -1.10 |
| Shares | 36.01M |
| Beta | - |
| Inst. own | 22% |
Events
May 29, 2013
Regulus Therapeutics at 38th Annual dbAccess Health Care Conference -
May 14, 2013
Q1 2013 Regulus Therapeutics Earnings Conference Call
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -223.26% | -137.07% |
| Operating margin | -225.79% | -136.07% |
| EBITD margin | - | -91.00% |
| Return on average assets | -28.92% | -23.78% |
| Return on average equity | -49.16% | -169.02% |
| Employees | 72 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 210, 3545 John Hopkins Court
SAN DIEGO, CA 92121
United States - Map
+1-858-2026300 (Phone)
+1-302-6555049 (Fax)
SAN DIEGO, CA 92121
United States - Map
+1-858-2026300 (Phone)
+1-302-6555049 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Volume delayed by 15 mins.
Advertisement
Description
Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing first-in-class drugs that target microRNAs to treat a range of diseases. microRNAs are naturally occurring ribonucleic acid, (RNA), molecules that play a critical role in regulating key biological pathways. The Company uses microRNA product platform to develop chemically modified, single-stranded oligonucleotides which it calls anti-miRs. It uses these anti-miRs to modulate microRNAs and by doing so return diseased cells to their healthy state. In August 2012, the Company formed a strategic alliance with AstraZeneca to discover and develop microRNA therapeutics for cardiovascular diseases, metabolic diseases and oncology.
Officers and directors
| John M. Maraganore Ph.D. | Chairman of the Board | |
| Kleanthis G. Xanthopoulos Ph.D. | President, Chief Executive Officer, Director | |
| Garry E. Menzel Ph.D. | Chief Operating Officer, Executive Vice President - Finance | |
| Neil W. Gibson Ph.D. | Chief Scientific Officer | |
| Mark G. Foletta CPA | Director | |
| B. Lynne Parshall J.D. | Director | |
| William H. Rastetter Ph.D. | Director | |
| Douglas E. Williams Ph.D. | Director | |
| David Baltimore Ph.D. | Independent Director |